

Lung GVHD Consortium Meeting Inventory

June 2021 – Present

Date	Guest Speaker	Research Topic
June 24, 2021	Dr. Ajay Sheshadri, MSCI, MD Anderson Cancer Center	Biomarkers for early detection
July 22, 2021	Dr. Joe Hsu, Stanford University	STOP-BOS translational data
August 26, 2021	Dr. Guang-Shing Cheng, Fred Hutchinson Cancer Center	New RV-BOS Study Protocol and Shared Data and Specimen Repository
September 2021	No Meeting	--
October 21, 2021	Dr. Xiaofeng Zhou, PhD, University of Michigan	Microbiome in BMT preclinical models
November 2021	No Meeting	--
December 9, 2021	Dr. Jane Turner, McMaster University	MRI in patients at risk for lung GVHD
January 27, 2022	Dr. Ajay Sheshadri, MSCI, MD Anderson Cancer Center	Biomarkers for BOS
February 17, 2022	Drs. Greg Yanik and Craig Galban, PhD, University of Michigan	Parametric Response Mapping and Lung GVHD
March 17, 2022	Dr. Sophie Paczesny, PhD, Medical University of South Carolina (MUSC)	Type 2 Lung innate lymphocyte cells in acute lung injury
April 2022	No Meeting	--
May 5, 2022	Drs. David Michonneau, PhD, and Anne Bergeron, PhD, Hôpital Saint-Louis, Paris, France	Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation
June 16, 2022	Dr. Guang-Shing Cheng, Fred Hutchinson Cancer Center	No Research Presentation – Lung GVHD: Where do we stand in 2022?
July 28, 2022	Dr. Anne Bergeron, PhD, Hôpital Saint-Louis, Paris, France	Roundtable: Perspective from an ILD-ologist
August 2022	No Meeting	--
September 22, 2022	Kirsten Williams, ARNP, Emory University	New Proposal in Pediatric Chronic Lung Disease after HCT
October 27, 2022	Dr. Ajay Sheshadri, MSCI, MD Anderson Cancer Center	Nasal Inflammation as a Surrogate for Airway Inflammation in Early Lung GVHD

Lung GVHD Consortium Meeting Inventory

June 2021 – Present

Date	Guest Speaker	Research Topic
November 17, 2022	Dr. Mark Barash, Medical College of Wisconsin	Two cases of serositis and pleural effusions
December 2022	No Meeting – HOLIDAYS	--
January 19, 2023	Susan Stewart, Executive Director BMT InfoNet	Patient Advocacy in GVHD and BMT InfoNet
	Patient Advocacy Group Sarah Johnson, Dena Fantle, Steven Arnold, and Courtney Guadiz	The Patient Perspective on Research in Lung GVHD
February 23, 2023	Dr. David Epstein, Stanford University	Impact of bronchiectasis and associated NTM and other respiratory tract infections on outcomes in BOS
March 30, 2023	No Meeting – Cancelled	--
April 27, 2023	Dr. Husham Sharifi, Stanford University	Strain maps of CT chest scans for detection of Early BOS
May 25, 2023	Dr. Matt Zinter, University of California, San Francisco	Case Presentation (UCSF) of a 5-year-old with lung GVHD and unusual pathology
June 22, 2023	Dr. Ajay Sheshadri, MSCI, MD Anderson Cancer Center	Using an in-vivo epithelial stem cell model to understand the biology of post-HCT BOS
July 20, 2023	Dr. Kirsten Williams, Emory University School of Medicine	Potential Consortium Projects: Retro Pathology Review
August 24, 2023	Dr. Guang-Shing Cheng, Fred Hutchinson Cancer Center	23 yo with BO and Recurrent Pneumothorax After HCT
September 22, 2023	Host, Dr. Guang-Shing Cheng, Fred Hutchinson Cancer Center	In-Person Lung GVHD Retreat in Seattle, WA
November 1, 2023	Dr. Ajay Sheshadri, MD Anderson Cancer Center	U54 Rare Diseases Clinical Research Consortia (RDCRC)
December 14, 2023	Dr. Eric D. Morell, University of Washington School of Medicine	BOS in Lung vs Bone Marrow Transplant Recipients: Can We Leverage Different Diseases to Identify Therapies?
January 25, 2024	Dr. Joshua Hill, Fred Hutchins Cancer Research	HHV-6B as a Pulmonary Pathogen After HCT: What is the Evidence?
February 29, 2024	Dr. Guang-Shing Cheng, Fred Hutchinson Cancer Center	BOS and Lung Complications / Tandem 2024 Highlights
March 20, 2024	Dr. Ajay Sheshadri, MD Anderson Cancer Center	Serum Biomarkers in Patients with Post-HCT BOS

Lung GVHD Consortium Meeting Inventory

June 2021 – Present

Date	Guest Speaker	Research Topic
April 25, 2024	Dr. Hemang Yadav, Mayo Clinic College of Medicine	Predicting Acute Respiratory Failure After HCT
May 23, 2024	Dr. Sam Goldfarb, University of Minnesota Medical School	<i>TRANSPIRE</i> and Highlights from ATS
June – Sept, 2024	No Meetings – summer break	--
October 24, 2024	Dr. Louise Bondeelle, University of Geneva	Interaction between respiratory viral infection and airway epithelial cells in the context of transplantation: a trigger for lung function impairment
November 21, 2024	Dr. Zachariah DeFilipp, MGH and Harvard Medical School	A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT
December 19, 2024	Dr. Katrin Hostettler, University Hospital Basel	Transbronchial lung cryobiopsy in the diagnosis of chronic pulmonary GVHD – a rising star?
January 30, 2025	Dr. Jeffrey Sturek, University of Virginia School of Medicine	Innate B Cells and Natural Antibodies in Lung Injury and Repair
February 27, 2025	Dr. Rabi Hanna, Cleveland Clinic, and Dr. Matt Zinter, UCSF	Case presentations: Is it BOS, or is it not BOS?
March 27, 2025	Dr. Kirsten Williams, Emory University	Research to enhance our understanding of lung cGVHD after HCT -A novel organoid model -Comparison of BOS and RLD immune signatures -Developing a new BAL for children
April 24, 2025	Dr. Husham Sharifi, Stanford University, and Dr. Faizyab Chaudrari, University of Alabama School of Medicine	Dr Husham Sharifi CT strain metrics allow for earlier diagnosis of bronchiolitis obliterans syndrome after hematopoietic cell transplant Dr. Muhammad Faizyab Ali Chaudrari Single volume surrogates of lung function
May 22, 2025	Dr. Annie Im, University of Pittsburgh	Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
June 26, 2025	Dr. Xiaofeng Zhou, University of Michigan	Lactobacillus johnsonii attenuates post-HCT pulmonary fibrosis via PD-L1/PD-1 axis
July 24, 2025	Dr. Mark Barash, Medical College of Wisconsin	Case discussion and clinical gaps

Lung GVHD Consortium Meeting Inventory

June 2021 – Present

Date	Guest Speaker	Research Topic
August 28, 2025	Dr. Hrish Kulkarni, University of California, Los Angeles	<i>Impaired complement regulation drives accelerated obliterative bronchiolitis after lung transplantation: opportunities for exploration in BMT</i>
September 25, 2025	Group discussion	<i>Open Discussion: How would you define Lung GVHD?</i>
October 23, 2025	Margherita Paschini, PhD, Boston Children's Hospital, and Corey Cutler, MD MPH, Harvard/Dana-Farber Cancer Institute	<i>Lung organoids from bronchoalveolar lavage to study GVHD</i> <i>Review of Novel Immunosuppressants in BOS</i>
November 20, 2025	Dr. Gordon Smilnak, University of Virginia, Dr. Felipe Soto, Indiana University, and Dr. Nicola Adderley, FHCC Visiting Investigator and Pulmonologist	<i>-Race-neutral Pulmonary Function Testing in Risk Stratification of Patients Undergoing Autologous Hematopoietic Cell Transplantation</i> <i>-Work-in-Progress: Allogeneic HCT risk stratification and eligibility with race-neutral pulmonary equations</i> <i>-Research Proposal: Implications of GLI 2022 equations for diagnosis of BOS after HCT</i>
December 18, 2025	Dr. Santoush Thyagu, University of Ottawa and Dr. Guang-Shing Cheng, Fred Hutch Cancer Center	<i>-Worsening shortness of breath 18 years s/p MRD-HSCT for MDS with a history of cGVHD and BOS</i> <i>- Persistent cough 3 years s/p second HCT for relapsed AML</i>